Collegium Pharmaceutical Inc
Company Profile
Business description
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Contact
100 Technology Center Drive
StoughtonMA02072
USAT: +1 781 713-3699
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
197
Stocks News & Analysis
stocks
DeepSeek revelation hits US chip stocks, ASX data centres and uranium
video
What does a weak Aussie dollar mean for investors?
stocks
AI stock rout: The US selloff in 4 charts
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,752.90 | 52.20 | 0.60% |
| CAC 40 | 7,872.48 | 24.89 | -0.32% |
| DAX 40 | 21,637.53 | 206.95 | 0.97% |
| Dow JONES (US) | 44,713.52 | 136.83 | -0.31% |
| FTSE 100 | 8,557.81 | 23.94 | 0.28% |
| HKSE | 20,225.11 | 27.34 | 0.14% |
| NASDAQ | 19,632.32 | 101.26 | -0.51% |
| Nikkei 225 | 39,523.51 | 108.73 | 0.28% |
| NZX 50 Index | 12,928.38 | 74.66 | -0.57% |
| S&P 500 | 6,039.31 | 28.39 | -0.47% |
| S&P/ASX 200 | 8,500.50 | 53.50 | 0.63% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |